Zevra Therapeutics Stock Quote ZVRA - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

4.82

Bid

4.76

Ask

8.25

Volume

250,744

4.77 Day's Range 5.05

3.89 52 Week Range 7.28

Market Cap

174.934M

Previous Close

5.03

Open

4.95

Last Trade

5.05

Last Trade Time

Financial Volume

$ 1,230,274

VWAP

4.9065

Average Volume (3m)

241,878

Shares Outstanding

36,218,164

Dividend Yield

PE Ratio

-3.80

Earnings Per Share (EPS)

-1.27

Revenue

27.46M

Net Profit

-46.05M

Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and ... Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.kempharm.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Zevra Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZVRA. The last closing price for Zevra Therapeutics was $5.03. Over the last year, Zevra Therapeutics shares have traded in a share price range of $ 3.89 to $ 7.28.

Zevra Therapeutics currently has 36,218,164 shares outstanding. The market capitalization of Zevra Therapeutics is $174.93 million. Zevra Therapeutics has a price to earnings ratio (PE ratio) of -3.80.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Zevra Therapeutics to Participate at Upcoming Investor Events

CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane...

Form 8-K - Current report

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~75% of covered lives as of May 1, 2024 Arimoclomol NDA review underway with PDUFA date of September...

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

CELEBRATION, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will host a...

Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F...

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

The oral presentation highlighted data from Zevra’s Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.01	-0.207039337474	4.83	5.3	4.77	240991	5.09275974	CS
4	-0.08	-1.63265306122	4.9	5.3	4.39	193434	4.76482514	CS
12	-1.81	-27.3001508296	6.63	7.28	4.39	241878	5.61567038	CS
26	0.61	14.4893111639	4.21	7.28	3.89	253274	5.56456322	CS
52	0.32	7.11111111111	4.5	7.28	3.89	228075	5.36510714	CS
156	-0.83	-14.6902654867	5.65	7.28	3.89	234151	5.32252351	CS
260	-0.83	-14.6902654867	5.65	7.28	3.89	234151	5.32252351	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
LIDRAEye Inc	$ 2.5406 (111.72%)	158.99M
NVAXNovavax Inc	$ 8.90 (98.66%)	170.86M
LGHLWLion Group Holding Ltd	$ 0.0059 (63.89%)	372.41k
ITOSiTeos Therapeutics Inc	$ 17.44 (43.07%)	5.26M
SRTSSensus Healthcare Inc	$ 5.3194 (39.62%)	19.74M
MGNXMacroGenics Inc	$ 3.31 (-77.44%)	35.15M
EVLVEvolv Technologies Holdings Inc	$ 2.355 (-38.67%)	14.74M
GWAVGreenwave Technology Solutions Inc	$ 0.0435 (-37.77%)	91.14M
SGDSafe and Green Development Corporation	$ 0.576 (-32.05%)	6.54M
NBSTWNewbury Street Acquisition Corporation	$ 0.0695 (-30.50%)	10.52k
NVAXNovavax Inc	$ 8.90 (98.66%)	170.86M
LIDRAEye Inc	$ 2.5406 (111.72%)	158.99M
NKLANikola Corporation	$ 0.537 (-6.77%)	113.59M
FFIEFaraday Future Intelligent Electric Inc	$ 0.0458 (12.81%)	101.35M
SQQQProShares UltraPro Short QQQ	$ 10.61 (-0.66%)	99.85M